Glucose-dependent insulinotropic polypeptide (GIP) dose-dependently reduces osteoclast differentiation and resorption.

@article{Mabilleau2016GlucosedependentIP,
  title={Glucose-dependent insulinotropic polypeptide (GIP) dose-dependently reduces osteoclast differentiation and resorption.},
  author={Guillaume Mabilleau and Rodolphe Perrot and Aleksandra Mieczkowska and S{\'e}bastien Boni and Peter Raymond Flatt and Nigel Irwin and Daniel Chappard},
  journal={Bone},
  year={2016},
  volume={91},
  pages={
          102-12
        }
}
A role for glucose-dependent insulinotropic polypeptide (GIP) in controlling bone resorption has been suspected. However uncertainty remains to identify whether GIP act directly on osteoclasts. The aim of the present study were (i) to identify in different osteoclast differentiation models (human peripheral blood mononuclear cells-PBMC, murine bone marrow macrophage-BMM and murine Raw 264.7 cells) whether GIP was capable of reducing osteoclast formation and resorption; (ii) ascertain whether… CONTINUE READING
2
Twitter Mentions

References

Publications referenced by this paper.
SHOWING 1-10 OF 51 REFERENCES

Incretins and bone: friend or foe?

  • Current opinion in pharmacology
  • 2015
VIEW 1 EXCERPT

Glucose-dependent insulinotropic polypeptide inhibits bone resorption in humans.

  • The Journal of clinical endocrinology and metabolism
  • 2014
VIEW 3 EXCERPTS

Gas - tric inhibitory polypeptide as an endogenous factor promoting new bone formation after food ingestion

Y. Yamada K. Tsukiyama, C. Yamada, +11 authors Y. Seino
  • Mol . Endocrinol .
  • 2013